{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+Medicinal+Product", "query": { "intervention": "Reference Medicinal Product" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 198, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+Medicinal+Product&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T21:15:38.947Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07049055", "title": "A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer, Metastatic", "PDAC - Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "E-EDV-D682", "type": "DRUG" }, { "name": "EDV-GC", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Engeneic Pty Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2026-01-12", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-11T21:15:38.947Z", "location_count": 4, "location_summary": "El Segundo, California • Summit, New Jersey • New York, New York + 1 more", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Summit", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Maumee", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07049055" }, { "nct_id": "NCT02806219", "title": "Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Prefilled syringe (PFS)", "type": "DEVICE" }, { "name": "e-Device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "UCB BIOSCIENCES, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 100, "start_date": "2016-03", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2016-11-17", "last_synced_at": "2026-09-11T21:15:38.947Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02806219" }, { "nct_id": "NCT02260492", "title": "Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "OT329 (combination of fluticasone propionate and salmeterol xinafoate)", "type": "DRUG" }, { "name": "Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oriel Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 879, "start_date": "2014-09", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2017-06-15", "last_synced_at": "2026-09-11T21:15:38.947Z", "location_count": 47, "location_summary": "Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02260492" }, { "nct_id": "NCT03650361", "title": "Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Adapalene Gel 0.3%", "type": "DRUG" }, { "name": "Differin 0.3% Topical Gel", "type": "DRUG" }, { "name": "Adapalene Gel 0.3% Vehicle Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aleor Dermaceuticals Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Years to 40 Years" }, "enrollment_count": 755, "start_date": "2018-09-17", "completion_date": "2019-02-16", "has_results": false, "last_update_posted_date": "2019-04-26", "last_synced_at": "2026-09-11T21:15:38.947Z", "location_count": 9, "location_summary": "Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more", "locations": [ { "city": "Sherman Oaks", "state": "California" }, { "city": "Brandon", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miramar", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03650361" }, { "nct_id": "NCT07425236", "title": "Argus 2.0 Adoption Study", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1 Diabetes", "Diabetes Mellitus, Type 2", "Prediabetes" ], "interventions": [ { "name": "KOS Argus Continuous Glucose Monitoring System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "KOS Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 100, "start_date": "2026-04-19", "completion_date": "2027-08-19", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-09-11T21:15:38.947Z", "location_count": 1, "location_summary": "San Mateo, California", "locations": [ { "city": "San Mateo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07425236" }, { "nct_id": "NCT05635357", "title": "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane/Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 16989, "start_date": "2022-11-01", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-09-11T21:15:38.947Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05635357" }, { "nct_id": "NCT00829712", "title": "Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Dexmethylphenidate Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Pharmaceuticals USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2004-06", "completion_date": "2004-06", "has_results": true, "last_update_posted_date": "2024-08-19", "last_synced_at": "2026-09-11T21:15:38.947Z", "location_count": 1, "location_summary": "Saint Charles, Missouri", "locations": [ { "city": "Saint Charles", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00829712" }, { "nct_id": "NCT02823171", "title": "To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Treatment A: 400 mg Pacritinib P3CT", "type": "DRUG" }, { "name": "Treatment B: 400 mg of pacritinib FMI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2015-08", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-09-11T21:15:38.947Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02823171" }, { "nct_id": "NCT03304587", "title": "Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Polysomnography (PSG)", "type": "DIAGNOSTIC_TEST" }, { "name": "Rectal thermistor 400 Series", "type": "DIAGNOSTIC_TEST" }, { "name": "Bright blue-green light", "type": "OTHER" }, { "name": "Dim red light", "type": "OTHER" }, { "name": "Digital foot candle datalogging light meter", "type": "DIAGNOSTIC_TEST" }, { "name": "Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue", "type": "OTHER" }, { "name": "Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance", "type": "OTHER" }, { "name": "Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression", "type": "OTHER" }, { "name": "Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function", "type": "OTHER" }, { "name": "Pittsburgh Sleep Quality Index (PSQI)", "type": "OTHER" }, { "name": "Center for Epidemiological Studies - Depression", "type": "OTHER" }, { "name": "Montreal Cognitive Assessment (MoCA)", "type": "OTHER" }, { "name": "European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)", "type": "OTHER" }, { "name": "Daily Log", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Michigan State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2017-11-06", "completion_date": "2022-08-31", "has_results": true, "last_update_posted_date": "2025-06-10", "last_synced_at": "2026-09-11T21:15:38.947Z", "location_count": 1, "location_summary": "East Lansing, Michigan", "locations": [ { "city": "East Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03304587" }, { "nct_id": "NCT03015259", "title": "Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Budesonide/Formoterol fumarate dihydrate", "type": "DRUG" }, { "name": "Symbicort", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kindeva Drug Delivery", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1762, "start_date": "2016-12-29", "completion_date": "2018-02-08", "has_results": true, "last_update_posted_date": "2022-08-24", "last_synced_at": "2026-09-11T21:15:38.947Z", "location_count": 95, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03015259" } ] }